265 related articles for article (PubMed ID: 19671919)
1. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim.
Kuter DJ; Mufti GJ; Bain BJ; Hasserjian RP; Davis W; Rutstein M
Blood; 2009 Oct; 114(18):3748-56. PubMed ID: 19671919
[TBL] [Abstract][Full Text] [Related]
2. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia.
Janssens A; Rodeghiero F; Anderson D; Chong BH; Boda Z; Pabinger I; Červinek L; Terrell DR; Wang X; Franklin J
Ann Hematol; 2016 Jun; 95(7):1077-87. PubMed ID: 27130310
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.
Rodeghiero F; Stasi R; Giagounidis A; Viallard JF; Godeau B; Pabinger I; Cines D; Liebman H; Wang X; Woodard P
Eur J Haematol; 2013 Nov; 91(5):423-36. PubMed ID: 23927437
[TBL] [Abstract][Full Text] [Related]
4. Romiplostim: a review of its use in immune thrombocytopenia.
Keating GM
Drugs; 2012 Feb; 72(3):415-35. PubMed ID: 22316355
[TBL] [Abstract][Full Text] [Related]
5. [Progression of bone marrow fibrosis with reticulin and collagen hyperplasia during treatment with the thrombopoietin receptor agonist romiplostim in a patient with immune thrombocytopenia].
Kirito K; Komatsu N
Rinsho Ketsueki; 2013 Mar; 54(3):295-9. PubMed ID: 23676646
[TBL] [Abstract][Full Text] [Related]
6. Reversible bone marrow reticulin fibrosis as a side effect of romiplostim therapy for the treatment of chronic refractory immune thrombocytopenia.
Leung T; Lokan J; Turner P; Smith C
Pathology; 2011 Aug; 43(5):520-2. PubMed ID: 21753725
[No Abstract] [Full Text] [Related]
7. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim.
Cines DB; Gernsheimer T; Wasser J; Godeau B; Provan D; Lyons R; Altomare I; Wang X; Lopez A
Int J Hematol; 2015 Sep; 102(3):259-70. PubMed ID: 26201709
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.
Bussel JB; Kuter DJ; Pullarkat V; Lyons RM; Guo M; Nichol JL
Blood; 2009 Mar; 113(10):2161-71. PubMed ID: 18981291
[TBL] [Abstract][Full Text] [Related]
9. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.
Ghanima W; Junker P; Hasselbalch HC; Boiocchi L; Geyer JT; Feng X; Gudbrandsdottir S; Orazi A; Bussel JB
Br J Haematol; 2011 Oct; 155(2):248-55. PubMed ID: 21902682
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.
Kuter DJ; Bussel JB; Lyons RM; Pullarkat V; Gernsheimer TB; Senecal FM; Aledort LM; George JN; Kessler CM; Sanz MA; Liebman HA; Slovick FT; de Wolf JT; Bourgeois E; Guthrie TH; Newland A; Wasser JS; Hamburg SI; Grande C; Lefrère F; Lichtin AE; Tarantino MD; Terebelo HR; Viallard JF; Cuevas FJ; Go RS; Henry DH; Redner RL; Rice L; Schipperus MR; Guo DM; Nichol JL
Lancet; 2008 Feb; 371(9610):395-403. PubMed ID: 18242413
[TBL] [Abstract][Full Text] [Related]
11. Romiplostim in chronic immune thrombocytopenic purpura.
Cersosimo RJ
Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
[TBL] [Abstract][Full Text] [Related]
12. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
[TBL] [Abstract][Full Text] [Related]
13. Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia.
Mokhtar GM; Tantawy AA; El Sherif NH
Platelets; 2012; 23(4):264-73. PubMed ID: 22471399
[TBL] [Abstract][Full Text] [Related]
14. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura.
Shirasugi Y; Ando K; Hashino S; Nagasawa T; Kurata Y; Kishimoto Y; Iwato K; Ohtsu T; Berger DP
Int J Hematol; 2009 Sep; 90(2):157-165. PubMed ID: 19543952
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia.
Michel M; Wasser J; Godeau B; Aledort L; Cooper N; Tomiyama Y; Khellaf M; Wang X
Ann Hematol; 2015 Dec; 94(12):1973-80. PubMed ID: 26341755
[TBL] [Abstract][Full Text] [Related]
16. Highly fluctuating thrombocytopenia developing in a patient with immune thrombocytopenia (ITP) while administering romiplostim.
Shinohara K; Kambara N
Intern Med; 2012; 51(11):1399-401. PubMed ID: 22687850
[TBL] [Abstract][Full Text] [Related]
17. Romiplostim: a novel thrombopoiesis-stimulating agent.
Perreault S; Burzynski J
Am J Health Syst Pharm; 2009 May; 66(9):817-24. PubMed ID: 19386944
[TBL] [Abstract][Full Text] [Related]
18. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
Jamali F; Lemery S; Ayalew K; Robottom S; Robie-Suh K; Rieves D; Pazdur R
Oncology (Williston Park); 2009 Jul; 23(8):704-9. PubMed ID: 19711585
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia.
Bussel JB; Buchanan GR; Nugent DJ; Gnarra DJ; Bomgaars LR; Blanchette VS; Wang YM; Nie K; Jun S
Blood; 2011 Jul; 118(1):28-36. PubMed ID: 21502541
[TBL] [Abstract][Full Text] [Related]
20. Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim.
Bussel JB; Wang X; Lopez A; Eisen M
Hematology; 2016 May; 21(4):257-62. PubMed ID: 26251926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
